According to an article from Cannabis Health News, there are more than 450 cannabinoid clinical trials that have taken place or are currently underway around the world¹. Most of these trials are taking place in the US, where there is a large population pool, a developed network of experienced investigators, a supportive regulatory framework, and a vast market of drug consumption that all combine to support expansion in clinical trials¹.

The UK and the Netherlands are currently responsible for around 71 percent of the active cannabinoids clinical trials in Europe, a reflection of the fact that these countries were among the first movers in easing the regulatory and legal barriers to commercial research and clinical trials¹.

Some examples of ongoing cannabis trials include:

• T21: The UK’s largest Medical Cannabis observational study. It allows patients to access certain qualifying medical cannabis products at a discounted price while collecting data to build up the real-world evidence on the effects of Cannabis-Based Medicinal Products (CBMPs) ².
• Flora Growth: A US cannabis producer that is conducting a human pilot study exploring the effects of medical cannabis in patients with fibromyalgia and chronic pain ³.
• University of Birmingham: Coordinating a major UK trial to analyze the efficacy of cannabis-based drug Sativex in treating the most aggressive form of brain t

Learn more:

1. cannabishealthnews.co.uk2. drugscience.org.uk3. clinicaltrialsregister.eu4. birmingham.ac.uk5. independent.co.uk6. bbc.co.uk7. msn.com8. theguardian.

The Medical Cannabis Research Group at Imperial College London is conducting research on the effects of medical cannabis in patients with a range of conditions, including inflammation, cancer, and pain¹. The group is interested in the evaluation and development of novel cannabinoid therapies targeting inflammation and cancer, with a current focus on pancreatic ductal adenocarcinoma (PDAC), as well as acute/post-surgical, neuropathic, and cancer-related pain¹. They are also interested in clinical outcomes-based research and the use of Real World Evidence (RWE) in cannabinoid drug development¹.

In addition to this, Imperial College London researchers are collaborating with medical cannabis company EMMAC Life Sciences and The Institute of Cancer Research, London, to better understand the effectiveness of cannabis-based medicinal products for the treatment of cancer and acute pain². The researchers aim to provide robust data that will help bodies like the National Institute for Health and Care Excellence (NICE) determine whether or not cannabis-based medicinal products are safe and effective enough to recommend for given conditions²